Cytokinetics Inc CYTK
We take great care to ensure that the data presented and summarized in this overview for CYTOKINETICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYTK
View all-
Black Rock Inc. New York, NY14.7MShares$732 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$586 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$483 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$388 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$322 Million0.01% of portfolio
-
Bank Of America Corp Charlotte, NC4.83MShares$241 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.16MShares$158 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA2.85MShares$142 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY2.72MShares$136 Million2.29% of portfolio
-
Polar Capital Holdings PLC London, X02.34MShares$117 Million0.76% of portfolio
Latest Institutional Activity in CYTK
Top Purchases
Top Sells
About CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Insider Transactions at CYTK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$250,000
$50.55 P/Share
|
|
Nov 18
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.23%
|
$30,000
$6.67 P/Share
|
|
Nov 12
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
6,342
-2.66%
|
$367,836
$58.48 P/Share
|
|
Nov 12
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.22%
|
$37,100
$7.96 P/Share
|
|
Nov 01
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$255,000
$51.63 P/Share
|
|
Nov 01
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.23%
|
$30,000
$6.67 P/Share
|
|
Oct 30
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-3.02%
|
$372,300
$51.92 P/Share
|
|
Oct 30
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.16%
|
$37,100
$7.96 P/Share
|
|
Oct 28
2024
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
4,452
-15.35%
|
$231,504
$52.25 P/Share
|
|
Oct 28
2024
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,452
+13.3%
|
$31,164
$7.37 P/Share
|
|
Oct 15
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-2.97%
|
$394,200
$54.19 P/Share
|
|
Oct 15
2024
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+4.09%
|
$37,100
$7.96 P/Share
|
|
Oct 09
2024
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.24%
|
$275,000
$55.61 P/Share
|
|
Oct 09
2024
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.23%
|
$30,000
$6.67 P/Share
|
|
Oct 01
2024
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
118
+0.48%
|
$6,136
$52.6 P/Share
|
|
Oct 01
2024
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
237
+0.93%
|
$12,324
$52.6 P/Share
|
|
Oct 01
2024
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
403
+1.04%
|
$20,956
$52.6 P/Share
|
|
Oct 01
2024
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
237
+1.48%
|
$12,324
$52.6 P/Share
|
|
Oct 01
2024
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
118
+0.51%
|
$6,136
$52.6 P/Share
|
|
Oct 01
2024
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
7,300
-2.96%
|
$379,600
$52.1 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 219K shares |
|---|---|
| Exercise of conversion of derivative security | 387K shares |
| Open market or private sale | 507K shares |
|---|---|
| Payment of exercise price or tax liability | 69.8K shares |
| Bona fide gift | 2.11K shares |